share_log

BioVie | 8-K: Current report

SEC ·  Aug 1, 2024 16:46

Summary by Moomoo AI

On July 29, 2024, BioVie Inc. held a special meeting where stockholders approved a reverse stock split of the company's Class A common stock. The board of directors was granted the authority to implement a reverse split ratio between 1-for-6 and 1-for-10, which was decided to be 1-for-10. The reverse stock split was filed with the Secretary of State of Nevada on July 31, 2024, and will take effect at 12:01 am Eastern Time on August 6, 2024. As a result, every ten shares of issued and outstanding common stock will be reclassified into one share. The reverse stock split will proportionally reduce the number of shares issuable upon the exercise or vesting of outstanding stock options, restricted stock units, and warrants, and will proportionally increase...Show More
On July 29, 2024, BioVie Inc. held a special meeting where stockholders approved a reverse stock split of the company's Class A common stock. The board of directors was granted the authority to implement a reverse split ratio between 1-for-6 and 1-for-10, which was decided to be 1-for-10. The reverse stock split was filed with the Secretary of State of Nevada on July 31, 2024, and will take effect at 12:01 am Eastern Time on August 6, 2024. As a result, every ten shares of issued and outstanding common stock will be reclassified into one share. The reverse stock split will proportionally reduce the number of shares issuable upon the exercise or vesting of outstanding stock options, restricted stock units, and warrants, and will proportionally increase the exercise prices of these instruments. No change will occur in the total number of authorized shares of common or preferred stock, and no fractional shares will be issued. Stockholders who would receive a fractional share will instead receive one full share of post-reverse stock split common stock. West Coast Stock Transfer, Inc. will act as the exchange agent for the reverse stock split. Stockholders holding shares in book-entry form or through a broker, bank, or other holder of record do not need to take any action. Trading of BioVie's common stock on The Nasdaq Capital Market will continue on a reverse stock split-adjusted basis starting August 6, 2024, under the new CUSIP number 09074F405.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more